Bullous pemphigoid (BP) patients were vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection because they have similar risk factors, so we should pay attention to patients with BP during the epidemic of coronavirus disease-19 (COVID-19). As far as treatment is concerned, many strategies for BP were changed during the epidemic. Plasmapheresis not only has been included in the guidelines for BP but also has been used successfully to rescue COVID-19 patients, especially in severe cases. Therefore, it is a feasible choice for BP patients, especially for refractory BP patients, infected with SARS-CoV-2. Apart from these, we have reviewed some points for attention during the plasmapheresis session.
第一作者机构：[1]Fourth Hosp Hebei Med Univ, Dept Dermatol, 12 Jiankang Rd, Shijiazhuang 050000, Hebei, Peoples R China
通讯作者：
通讯机构：[1]Fourth Hosp Hebei Med Univ, Dept Dermatol, 12 Jiankang Rd, Shijiazhuang 050000, Hebei, Peoples R China[*1]Department of Dermatology The Fourth Hospital of Hebei Medical University No. 12 Jiankang Road Shijiazhuang Hebei Province, 050000 P.R. China
推荐引用方式(GB/T 7714)：
Cui Yu,Hu Caixia,Cheng Yi,et al.Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2[J].INTERNATIONAL JOURNAL OF DERMATOLOGY.2022,61(2):252-256.doi:10.1111/ijd.15892.
APA：
Cui, Yu,Hu, Caixia,Cheng, Yi,Han, Xiaomei&Wang, Wenqing.(2022).Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2.INTERNATIONAL JOURNAL OF DERMATOLOGY,61,(2)
MLA：
Cui, Yu,et al."Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2".INTERNATIONAL JOURNAL OF DERMATOLOGY 61..2(2022):252-256
